FOR IMMEDIATE RELEASE

Pasture Holdings builds second-half momentum and advances regional healthcare strategy

New supply routes supported a second-half recovery as the Group expanded its healthcare activities in Malaysia and progressed plans to own selected product lines.

- New supply lines and distribution routes supported a sequential revenue recovery and materially narrowed losses in 2H2026.
- APB expanded Pasture's regional healthcare presence through corporate wellness programme, screening over 600 individuals in Malaysia.
- The Group is actively in discussions to develop, manufacture and own selected healthcare product lines, with the aim of increasing its participation across the healthcare value chain.

Singapore, 21 August 2026 – Pasture Holdings Ltd. ("**Pasture**" or the "**Company**", and together with its subsidiaries, the "**Group**") today announced its six months and full year results for the financial year ended 30 June 2026 ("**FY2026**").

Second-half recovery following first-half disruption

Pasture entered second half of FY2026 ("**2H2026**") with strengthened supply capabilities and new distribution routes within its core Pharmaceutical Wholesale and Drop-Shipment ("**Pharma WDS**") business, enabling the Group to rebuild shipment volumes following significant external disruption in first half of FY2026 ("**1H2026**").

Key operational milestones during the period included:

- the activation of new pharmaceutical supply lines and distribution routes;
- the restoration of shipment activity following changes in tariffs and customs requirements;
- a material improvement in revenue during 2H2026; and
- a significant reduction in the Group's 2H2026 net loss.

Demand remained strong throughout 1H2026 and 2H2026. However, tariff-related and regulatory disruptions constrained the Group's ability to deliver products to customers in 1H2026 resulting in delayed fulfilment of orders. These disruptions eased during 2H2026 and the Group was able to restore deliveries. Revenue increased from US$4.26 million in 1H2026 to US$5.24 million in 2H2026, an increase of 23.2%. The increase was mainly contributed the Pharma WDS business.

Correspondingly, gross profit margin improved to 22.5% in 2H2026 from 16.9% in 1H2026.

The Group aims to drive continued growth in its Pharma WDS operations by further strengthening and improvising the distribution network implemented in 2H2026.

Growing regional network

The Group continued to expand its presence in Malaysia's healthcare industry through its joint venture, AP Bioresources Sdn Bhd ("**APB**").

In FY2026, APB implemented its corporate health-screening programme and initiated long-term engagement with employers and organisations seeking to enhance access to preventive healthcare for their staff.

Under this corporate health-screening programme, APB has successfully carried out screenings programmes for corporate clients, reaching over 600 individuals.

APB remains focused on scaling its operations and strengthening its healthcare-screening, healthcare-distribution and customer-engagement capabilities.

Building greater ownership across the healthcare value chain

Looking ahead, the Group intends to progressively expand beyond distribution by evaluating opportunities to develop, manufacture and own selected pharmaceutical, medical and healthcare product lines, increasing its share in the healthcare value chains.

In the near-term, the Group expects tariff- and regulatory-related uncertainties to persist into FY2027, and likely to have an impact on margins.

Mr Lloyd Soong, Executive Chairman and Chief Executive Officer of Pasture Holdings, said:

"As Pasture celebrates our 30 years anniversary, we are taking greater ownership of where and how we create value. We will focus on leveraging our regulatory expertise, distribution capabilities, supplier relationships and expanding regional healthcare network. We are engaged in discussions with our manufacturing, product-development and commercial partners to bring selected niche products to market exclusively owned by Pasture."

##

About Pasture Holdings Ltd.

Pasture is a Singapore-based, SGX Catalist-listed pharmaceutical and medical supplies group, supplying over 2,000 third-party pharmaceutical products and medical supplies to customers in over 50 countries. Its wholesale and drop-shipment business includes cold-chain management for temperature-sensitive pharmaceutical products, a segment that has grown globally from US$272 billion in biopharma cold chain product sales in 2016 to US$440 billion in 2024 – a compound annual growth rate of approximately 6.2%[1].

Beyond wholesale distribution, Pasture develops and sells its own proprietary range of masks under the Pasture Masks brand, and manufactures HART-S, a sildenafil oral dissolving strip product. Pasture also operates furlife, a pet health platform, with customers in Singapore, Japan, Canada, and the United States.

For more information, please visit https://pasturegroup.com/

[1] Statista, Global biopharma cold chain product sales from 2016 to 2024. https://www.statista.com/statistics/303081/trend-in-biopharma-cold-chain-products-global-sales/

For media enquiries, please contact
Corporate Communications & Digital Marketing Manager
Claire Soong
Email: contact@pasturegroup.com
Tel: +65 6515 6516
